You are here » Home » Companies » Company Overview » Arvind Remedies Ltd

Arvind Remedies Ltd.

BSE: 531823 Sector: Health care
NSE: ARVINDREM ISIN Code: INE211C01037
BSE 00:00 | 04 Mar Arvind Remedies Ltd
NSE 05:30 | 01 Jan Arvind Remedies Ltd
OPEN 14.40
PREVIOUS CLOSE 15.05
VOLUME 919464
52-Week high 15.85
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 103
Buy Price 15.05
Buy Qty 424.00
Sell Price 0.00
Sell Qty 0.00
OPEN 14.40
CLOSE 15.05
VOLUME 919464
52-Week high 15.85
52-Week low 0.00
P/E
Mkt Cap.(Rs cr) 103
Buy Price 15.05
Buy Qty 424.00
Sell Price 0.00
Sell Qty 0.00

Arvind Remedies Ltd. (ARVINDREM) - Chairman Speech

Company chairman speech

CHAIRMANS STATEMENT

Dear Shareholders

FY 14 has been a good year for Arvind Remedies with growth in overall business andcommercialization of Unit 3 we are foraying our presence in the 1000cr Revenue mark. Weare much grateful to our esteemed shareholders for all their support and cooperationextended all along in the past. Our presence in Domestic market has increased to 30 ownbrands across acute and chronic segment. Currently our field force is covering 10 states.In the Generic segment we have a specialised team for In house sales & marketingpersonnel which has a good reach to Pan India. Going ahead we expect to explore moreopportunities to increase the number of product and the marketing territories for thedomestic segment. This year we have seen increase of contribution from the CRAMS segmentwhich we cater to various national and multinational companies in dosage forms of TabletsCapsules Dry Syrups Ointments Liquid Orals and Injectables. In the International marketwe are foraying into new regions and expect larger contributions in the marketing share inthe coming years. New products are also being developed with the patents registration.Looking at the need of drugs with less side effects and better efficacy we at ArvindRemedies are engaged in developments of dosage forms with unique USP. As a result sideeffect of existing formulation is reducing and bioavailability of drug or end pointtherapeutic effect is increasing. Currently we have products in the late clinical stage indifferent therapeutic segments like Neuro de-generation disorder Arthritis CardiacDepression and Viral Diseases. Needless to mention we look forward to your continuedsupport in bringing up ARL to the heights of global renown.

With good wishes